Should psychiatrists prescribe neuroenhancers for mentally healthy patients?

Psychiatric Times

Volumn 28, Issue 3, 2011, Pages

  Geppert, Cynthia M A ^a,b   Taylor, Peter J ^c  

^a Health Care System   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953885176     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Larriviere D, Williams MA, Rizzo M, Bonnie RJ; AAN Ethics, Law and Humanities Committee. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology 2009;73:1406-1412.
2. Talbot M. Brain gain: the underground world of "neuroenhancing" drugs. New Yorker. April 27, 2009:32-43.
3. Maher B. Poll results: look who's doping. Nature. 2008;452:674-675. (Pubitemid 351521058)
4. Cakic V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology [published correction appears in J Med Ethics. 2009;35:738].
5. J Med Ethics. 2009; 35:611-615.
6. Johnson K. Medications for cognitive enhancement in the healthy: psychiatrists' dilemma. Med-scape Medical News. 2010.
7. Flower K, Li L, Chen CY, et al. Efficacy, safety, and ethics of cosmetic neurology far from settled. Clin Pharmacol Ther. 2010;88:461-463.
8. Larriviere D, Williams MA. Neuroenhancement: wisdom of the masses or "false phronesis"? Clin Pharmacol Ther. 2010;88:459-461.
9. Kramer PD. Listening to Prozac. New York: Penguin Books; 1993.
10. de Jongh R, Bolt I, Schermer M, Olivier B. Botox for the brain: enhancement of cognition, mood and prosocial behavior and blunting of unwanted memories. Neurosci Biobehav Rev. 2008;32:760-776.
11. Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy Individuals: a systematic review. Pharmacol Res. 2010;61:473-481.
12. Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187-206.
13. Weyandt LL, Janusis G, Wilson KG, et al. Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables. JAtten Disord. 2009;13:284-296.
14. Weissman MM, Verdeli H, Gameroff MJ, et al. National survey of psychotherapy training in psychiatry, psychology, and social work. Arch Gen Psychiatry. 2006;63:925-934. (Pubitemid 44188485)
15. Olfson M, Marcus SC. National trends in outpatient psychotherapy. Am J Psychiatry. 2010;167: 1456-1463.
16. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301:2005-2015.
17. Hays KR, ed. Performance Psychology in Action: A Casebook for Working With Athletes, Performing Artists, Business Leaders, and Professionals in High-Risk Occupations. Washington, DC: American Psychological Association; 2009.
18. Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. N Engl J Med. 2007;357:1834-1840.
19. Roberts LW. Informed consent and the capacity for voluntarism. Am J Psychiatry. 2002;159:705-712. (Pubitemid 34465041)
20. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy [published correction appears in Nature. 2008;456:872].
21. Nature. 2008;456:702-705.
22. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886-891.
23. Chatterjee A. Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Camb Q Healthc Ethics. 2007;16:129-137.
24. Shorter E. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. New York: John Wiley & Sons; 1997.
25. Carlat D. 45,000 More psychiatrists, anyone? PsychiatrTimes. 2010;27(8):1-4.
26. Radden J, Sadler JZ. The Virtuous Psychiatrist: Character Ethics in Psychiatric Practice. New York: Oxford University Press; 2010.
27. Cerullo MA. Cosmetic Psychopharmacology and the President's Council on Bioethics. Perspect Biol Med. 2006;49:515-523.
28. Beglinger LJ, Tangphao-Daniels O, Kareken DA, et al. Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J Clin Psychopharmacol. 2005;25:159-165. (Pubitemid 40395094)
29. Clark CR, Geffen GM, Geffen LB. Role of monoamine pathways in attention and effort: effects of Clonidine and methylphenidate in normal adult humans. Psychopharmacology (Bert). 1986;90:35-39. (Pubitemid 16075158)
30. Gobbi G, Slater S, Boucher N, et al. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol. 2003;23: 233-239. (Pubitemid 36807790)
31. Rogers RD, Blackshaw AJ, Middleton HC, et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology (Bert). 1999;146:482-491. (Pubitemid 29513289)
32. Bray CL, Cahill KS, Oshier JT, et al. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. J Investig Med. 2004;52:192-201. (Pubitemid 38856422)
33. Randall DC, Shneerson JM, File SE. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol Biochem Behav. 2005;82:133-139. (Pubitemid 41423496)
34. Taneja I, Haman K, Shelton RC, Robertson D. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol. 2007; 27:76-79. (Pubitemid 46105770)
35. Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol. 2004;19:323-332. (Pubitemid 39106873)